Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | FNTA | P49354 | 8/20 | 0.47 |
| ▸ | FNTB | P49356 | 8/20 | 0.47 |
| ▸ | PGGT1B | P53609 | 8/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5507650 | 0.91 | LTA4H (0.58) | LTA4HFNTAFNTBPGGT1B | |
| SCHEMBL24191552 | 0.87 | F2 (0.49) | — | |
| Trifluoroacetic Acid SCHEMBL23630169 | 0.86 | LTA4H (0.53) | LTA4HFNTAFNTBPGGT1B | |
| Trifluoroacetic Acid SCHEMBL23630172 | 0.86 | LTA4H (0.53) | LTA4HFNTAFNTBPGGT1B | |
| SCHEMBL24191699 | 0.84 | CTSS (0.52) | LTA4H | |
| SCHEMBL11662915 | 0.83 | FNTA (0.49) | FNTAFNTBPGGT1B | |
| SCHEMBL11662923 | 0.83 | FNTA (0.49) | FNTAFNTBPGGT1B | |
| SCHEMBL24191597 | 0.82 | QRFPR (0.54) | — | |
| SCHEMBL30051473 | 0.82 | LTA4H (0.64) | LTA4HFNTAFNTBPGGT1B | |
| SCHEMBL30050877 | 0.82 | LTA4H (0.60) | LTA4HANPEPFNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | STING1, CGAS, TLR9 | LTA4H 1009/4885ANPEP 918/4885FNTA 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.